Polish company announces world’s first anti-COVID-19 medicine


Photo by Savanevich Viktar/Shutterstock.com

Polish pharmaceutical company Biomed Lublin announced that it has finished production of the first batch of medicine made of plasma obtained from those who recovered from COVID-19 disease, Polandin.com reports. 

Photo by Savanevich Viktar/Shutterstock.com

The medicine, created via the process of the fractionation of plasma from patients who recovered or showed no symptoms of COVID-19 but were infected, contains specific anti-SARS-CoV-2 immunoglobulins. It will be released for non-commercial clinical trials in fourth quarter of 2020, according to the company.

“More than 3,000 samples of anti-SARS-CoV-2 immunoglobulin have been produced, which after the completion of the required quality tests, including product stability tests, will be submitted for clinical trials in four centres: in Lublin, Bytom, Białystok and Warsaw,” said Marcin Piróg, CEO of Biomed.

A total of 81,673 confirmed cases of the COVID-19 coronavirus infections were recorded in Poland as of the morning of September 23, which have resulted in 2,344 deaths and 65,561 recoveries, Polandin.com said.


Swiss Companies Expanding in Hungary Analysis

Swiss Companies Expanding in Hungary

Horthy Statue to be Unveiled in Parliament Parliament

Horthy Statue to be Unveiled in Parliament

UPS Appoints Regional Director Appointments

UPS Appoints Regional Director

Completion of Metro Line M3 Renovation Delayed City

Completion of Metro Line M3 Renovation Delayed


Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.